SG11201509352XA - 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators - Google Patents
11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulatorsInfo
- Publication number
- SG11201509352XA SG11201509352XA SG11201509352XA SG11201509352XA SG11201509352XA SG 11201509352X A SG11201509352X A SG 11201509352XA SG 11201509352X A SG11201509352X A SG 11201509352XA SG 11201509352X A SG11201509352X A SG 11201509352XA SG 11201509352X A SG11201509352X A SG 11201509352XA
- Authority
- SG
- Singapore
- Prior art keywords
- farnesoid
- hydroxyl
- derivatives
- amino acid
- receptor modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823169P | 2013-05-14 | 2013-05-14 | |
| PCT/EP2014/059896 WO2014184271A1 (en) | 2013-05-14 | 2014-05-14 | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509352XA true SG11201509352XA (en) | 2015-12-30 |
Family
ID=50721801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509352XA SG11201509352XA (en) | 2013-05-14 | 2014-05-14 | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US9611289B2 (en) |
| EP (4) | EP2997035B8 (en) |
| JP (2) | JP6326131B2 (en) |
| KR (1) | KR102229952B1 (en) |
| CN (2) | CN108245523B (en) |
| AU (1) | AU2014267324B2 (en) |
| BR (1) | BR112015028399B1 (en) |
| CA (1) | CA2912139C (en) |
| CL (2) | CL2015003344A1 (en) |
| CR (1) | CR20150643A (en) |
| CY (1) | CY1122614T1 (en) |
| DK (4) | DK3360882T3 (en) |
| EA (1) | EA030152B1 (en) |
| ES (4) | ES2843737T3 (en) |
| GT (1) | GT201500324A (en) |
| HK (2) | HK1253326A1 (en) |
| HR (1) | HRP20180931T1 (en) |
| HU (1) | HUE037996T2 (en) |
| IL (2) | IL242555B (en) |
| LT (1) | LT2997035T (en) |
| MA (1) | MA38647B1 (en) |
| ME (1) | ME03082B (en) |
| MX (1) | MX352065B (en) |
| MY (1) | MY187886A (en) |
| NI (1) | NI201500160A (en) |
| PE (1) | PE20160665A1 (en) |
| PH (1) | PH12015502576A1 (en) |
| PL (3) | PL2997035T3 (en) |
| PT (3) | PT3360881T (en) |
| RS (1) | RS57372B1 (en) |
| SA (1) | SA515370140B1 (en) |
| SG (1) | SG11201509352XA (en) |
| SI (3) | SI2997035T1 (en) |
| TN (1) | TN2015000497A1 (en) |
| TR (1) | TR201809041T4 (en) |
| UA (1) | UA118673C2 (en) |
| WO (1) | WO2014184271A1 (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PT3360881T (en) | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| EP3149019B1 (en) | 2014-05-29 | 2019-12-04 | Bar Pharmaceuticals S.r.l. | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
| RU2017118569A (en) | 2014-11-06 | 2018-12-06 | Энанта Фармасьютикалс, Инк. | BILIC ACID ANALOGUES AS FXR / TGR5 AGONISTS AND WAYS OF THEIR APPLICATION |
| CN107108688B (en) | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 6 alpha-alkyl -3,7- diketone the steroids as the intermediate for preparing steroids FXR regulator |
| KR102527821B1 (en) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| EA033445B1 (en) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-beta-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| EP3221331B1 (en) | 2014-11-19 | 2019-09-18 | Nzp Uk Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) * | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| KR20170099909A (en) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| MA41094A (en) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | KIDNEY DISORDERS TREATMENT METHODS |
| CN105348365A (en) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | Cholic acid derivative and preparation method, pharmaceutical composition and application thereof |
| CN104523703A (en) * | 2014-12-24 | 2015-04-22 | 聂飚 | Application of free fatty acid translocator small-molecule inhibitor |
| DK3253382T3 (en) * | 2015-02-06 | 2022-02-14 | Intercept Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY |
| SG11201706089RA (en) | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US20180042943A1 (en) * | 2015-03-09 | 2018-02-15 | Intercept Pharmaceuticals, Inc. | Methods for modulating bone density |
| WO2016145216A1 (en) * | 2015-03-10 | 2016-09-15 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| JP2018510866A (en) * | 2015-03-13 | 2018-04-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Treatment of adult latent autoimmune diabetes with a farnesoid X receptor agonist to activate intestinal receptors |
| RU2712099C2 (en) * | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Bile acid derivatives as fxr/tgr5 agonists and methods for use thereof |
| EP3280421B1 (en) * | 2015-04-07 | 2023-12-27 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| WO2016168553A1 (en) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Deuterated obeticholic acid |
| PE20180690A1 (en) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | OBETICOLIC ACID COMPOSITIONS AND METHODS OF USE |
| CN106478759A (en) * | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | Shellfish chlolic acid derivatives difficult to understand and its production and use |
| JP6824966B2 (en) | 2015-09-21 | 2021-02-03 | インターセプト ファーマシューティカルズ， インコーポレイテッド | How to promote liver regeneration |
| AR106293A1 (en) * | 2015-10-07 | 2018-01-03 | Intercept Pharmaceuticals Inc | FARNESOID X RECEIVER MODULATORS |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147137A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10815267B2 (en) * | 2016-03-11 | 2020-10-27 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| CA3020698A1 (en) * | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating or preventing hepatocellular carcinoma |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| SI3730487T1 (en) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
| US10584145B2 (en) | 2016-11-29 | 2020-03-10 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| JP2020508316A (en) | 2017-02-21 | 2020-03-19 | ジェンフィＧｅｎｆｉｔ | Combination of PPAR agonist and FXR agonist |
| MX2019009861A (en) * | 2017-02-23 | 2020-07-14 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof. |
| CA3055581C (en) | 2017-03-28 | 2023-03-14 | Gilead Sciences, Inc. | Methods of treating liver disease |
| BR112019020780A2 (en) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | process for preparing sulfonyl carbamate bile acid derivatives |
| WO2018226724A1 (en) * | 2017-06-05 | 2018-12-13 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of diabetic eye diseases with a bile acid derivatives |
| WO2018237350A1 (en) * | 2017-06-23 | 2018-12-27 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| AU2018307611A1 (en) | 2017-07-24 | 2020-02-06 | Intercept Pharmaceuticals, Inc. | Isotopically labeled bile acid derivatives |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN109182451B (en) * | 2018-08-21 | 2021-06-11 | 四川大学 | Novel specific probe reaction of cytochrome CYP3A7 enzyme and application thereof |
| HRP20240265T1 (en) | 2019-01-15 | 2024-05-10 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| JP2022536060A (en) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Pharmaceutical composition comprising an FXR agonist and a fibrate for use in treating cholestatic liver disease |
| JP2022540699A (en) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | How to reduce the adverse effects of interferon |
| CN110540955B (en) * | 2019-08-28 | 2021-09-17 | 北京协同创新研究院 | Method for improving expression quantity of NROB2 gene in differentiated cell |
| CN114945361A (en) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Use of FXR agonists for the treatment of hepatitis delta virus infection |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| JP2024517181A (en) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | Strong enhancement of the effects of TLR3 agonists using FXR agonists as combination therapy |
| WO2022233398A1 (en) * | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080775A (en) * | 1934-08-22 | 1937-05-18 | Celanese Corp | Shedding mechanism for circular looms |
| US2802775A (en) * | 1953-05-29 | 1957-08-13 | Merck & Co Inc | 11 alpha-hydroxylation of steroids by aspergillus ochraceus |
| JPS59205396A (en) * | 1983-05-09 | 1984-11-20 | Kuraray Co Ltd | 11beta-hydroxypregn-4-en-3-one-20-carbaldehyde and production thereof |
| DE69940958D1 (en) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | DETERMINATION METHOD FOR LIGANDS OF NUCLEAR RECEPTORS |
| ITMI20021532A1 (en) * | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | CHEMICAL COMPOUNDS |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| HUE032928T2 (en) * | 2004-03-12 | 2017-11-28 | Intercept Pharmaceuticals Inc | Treatment of fibrosis using Fxr ligands |
| CA2656320C (en) * | 2006-06-27 | 2015-04-28 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
| PT3360881T (en) | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
-
2014
- 2014-05-14 PT PT181636226T patent/PT3360881T/en unknown
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/en active
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/en unknown
- 2014-05-14 SI SI201430701T patent/SI2997035T1/en unknown
- 2014-05-14 ES ES18163623T patent/ES2843737T3/en active Active
- 2014-05-14 PT PT181636234T patent/PT3360882T/en unknown
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/en not_active Expired - Fee Related
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en active Application Filing
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/en active Active
- 2014-05-14 ES ES18163622T patent/ES2847002T3/en active Active
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/en unknown
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/en unknown
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/en active
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/en active
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/en active Active
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 RS RS20180690A patent/RS57372B1/en unknown
- 2014-05-14 SI SI201431742T patent/SI3360881T1/en unknown
- 2014-05-14 PL PL14723820T patent/PL2997035T3/en unknown
- 2014-05-14 PT PT147238208T patent/PT2997035T/en unknown
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/en active IP Right Grant
- 2014-05-14 EA EA201592055A patent/EA030152B1/en unknown
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/en active Active
- 2014-05-14 MA MA38647A patent/MA38647B1/en unknown
- 2014-05-14 PL PL18163622T patent/PL3360881T3/en unknown
- 2014-05-14 MX MX2015015730A patent/MX352065B/en active IP Right Grant
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/en unknown
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 ES ES20211780T patent/ES2936638T3/en active Active
- 2014-05-14 UA UAA201511098A patent/UA118673C2/en unknown
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/en active IP Right Grant
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/en active
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/en unknown
- 2014-05-14 PL PL18163623T patent/PL3360882T3/en unknown
- 2014-05-14 SI SI201431741T patent/SI3360882T1/en unknown
-
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/en unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/en unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/en unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576A1/en unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/en unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/en unknown
-
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/en unknown
- 2016-08-15 HK HK18112619.6A patent/HK1253326A1/en unknown
- 2016-08-15 HK HK16109719.3A patent/HK1221471A1/en unknown
-
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
-
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/en not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/en unknown
- 2018-06-15 HR HRP20180931TT patent/HRP20180931T1/en unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
-
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
-
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
-
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272718B (en) | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
| HRP20181269T1 (en) | Peptides and compositions for treatment of joint damage | |
| SG11201604697TA (en) | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same | |
| HK1211295A1 (en) | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof c17- | |
| EP2892929A4 (en) | Methods and compositions for site-specific labeling of peptides and proteins | |
| EP2970928A4 (en) | Generation of acyl amino acids | |
| IL227890A0 (en) | Anti-aging compositions comprising bile acid and fatty acid conjugates | |
| IL240734A0 (en) | Methods and compositions for preparation of nucleic acids | |
| EP3004132A4 (en) | Bile acid-basic amino acid conjugates and uses thereof | |
| EP2922871A4 (en) | Methods and compositions for modified factor ix proteins | |
| TH1501006859A (en) | 11-hydroxyl derivatives and bile acids and their amino acid couplings as Farnesoid X Receptor Modulator |